Comparison of Glecaprevir/Pibrentasvir and Sofosbuvir/Ledipasvir in Patients with Hepatitis C Virus Genotype 1 and 2 in South Korea
CONCLUSIONS: Both regimens had similar treatment completion rates, effectiveness, and safety profiles. Therefore, the SOF/LDV regimen can also be considered a viable DAA for the treatment of patients with genotype 1 or 2 chronic hepatitis C.PMID:38522854 | DOI:10.4166/kjg.2023.141 (Source: Korean J Gastroenter...)
Source: Korean J Gastroenter... - March 24, 2024 Category: Gastroenterology Authors: Hyun Deok Shin Il Han Song Sae Hwan Lee Hong Soo Kim Tae Hee Lee Hyuk Soo Eun Seok Hyun Kim Byung Seok Lee Hee Bok Chae Seok Hwan Kim Myung Joon Song Soon Yeong Ko Suk Bae Kim Source Type: research
Comparison of Glecaprevir/Pibrentasvir and Sofosbuvir/Ledipasvir in Patients with Hepatitis C Virus Genotype 1 and 2 in South Korea
CONCLUSIONS: Both regimens had similar treatment completion rates, effectiveness, and safety profiles. Therefore, the SOF/LDV regimen can also be considered a viable DAA for the treatment of patients with genotype 1 or 2 chronic hepatitis C.PMID:38522854 | DOI:10.4166/kjg.2023.141 (Source: Korean J Gastroenter...)
Source: Korean J Gastroenter... - March 24, 2024 Category: Gastroenterology Authors: Hyun Deok Shin Il Han Song Sae Hwan Lee Hong Soo Kim Tae Hee Lee Hyuk Soo Eun Seok Hyun Kim Byung Seok Lee Hee Bok Chae Seok Hwan Kim Myung Joon Song Soon Yeong Ko Suk Bae Kim Source Type: research
Comparison of Glecaprevir/Pibrentasvir and Sofosbuvir/Ledipasvir in Patients with Hepatitis C Virus Genotype 1 and 2 in South Korea
CONCLUSIONS: Both regimens had similar treatment completion rates, effectiveness, and safety profiles. Therefore, the SOF/LDV regimen can also be considered a viable DAA for the treatment of patients with genotype 1 or 2 chronic hepatitis C.PMID:38522854 | DOI:10.4166/kjg.2023.141 (Source: Korean J Gastroenter...)
Source: Korean J Gastroenter... - March 24, 2024 Category: Gastroenterology Authors: Hyun Deok Shin Il Han Song Sae Hwan Lee Hong Soo Kim Tae Hee Lee Hyuk Soo Eun Seok Hyun Kim Byung Seok Lee Hee Bok Chae Seok Hwan Kim Myung Joon Song Soon Yeong Ko Suk Bae Kim Source Type: research
Comparison of Glecaprevir/Pibrentasvir and Sofosbuvir/Ledipasvir in Patients with Hepatitis C Virus Genotype 1 and 2 in South Korea
CONCLUSIONS: Both regimens had similar treatment completion rates, effectiveness, and safety profiles. Therefore, the SOF/LDV regimen can also be considered a viable DAA for the treatment of patients with genotype 1 or 2 chronic hepatitis C.PMID:38522854 | DOI:10.4166/kjg.2023.141 (Source: Korean J Gastroenter...)
Source: Korean J Gastroenter... - March 24, 2024 Category: Gastroenterology Authors: Hyun Deok Shin Il Han Song Sae Hwan Lee Hong Soo Kim Tae Hee Lee Hyuk Soo Eun Seok Hyun Kim Byung Seok Lee Hee Bok Chae Seok Hwan Kim Myung Joon Song Soon Yeong Ko Suk Bae Kim Source Type: research
Comparison of Glecaprevir/Pibrentasvir and Sofosbuvir/Ledipasvir in Patients with Hepatitis C Virus Genotype 1 and 2 in South Korea
CONCLUSIONS: Both regimens had similar treatment completion rates, effectiveness, and safety profiles. Therefore, the SOF/LDV regimen can also be considered a viable DAA for the treatment of patients with genotype 1 or 2 chronic hepatitis C.PMID:38522854 | DOI:10.4166/kjg.2023.141 (Source: Korean J Gastroenter...)
Source: Korean J Gastroenter... - March 24, 2024 Category: Gastroenterology Authors: Hyun Deok Shin Il Han Song Sae Hwan Lee Hong Soo Kim Tae Hee Lee Hyuk Soo Eun Seok Hyun Kim Byung Seok Lee Hee Bok Chae Seok Hwan Kim Myung Joon Song Soon Yeong Ko Suk Bae Kim Source Type: research
Comparison of Glecaprevir/Pibrentasvir and Sofosbuvir/Ledipasvir in Patients with Hepatitis C Virus Genotype 1 and 2 in South Korea
CONCLUSIONS: Both regimens had similar treatment completion rates, effectiveness, and safety profiles. Therefore, the SOF/LDV regimen can also be considered a viable DAA for the treatment of patients with genotype 1 or 2 chronic hepatitis C.PMID:38522854 | DOI:10.4166/kjg.2023.141 (Source: Korean J Gastroenter...)
Source: Korean J Gastroenter... - March 24, 2024 Category: Gastroenterology Authors: Hyun Deok Shin Il Han Song Sae Hwan Lee Hong Soo Kim Tae Hee Lee Hyuk Soo Eun Seok Hyun Kim Byung Seok Lee Hee Bok Chae Seok Hwan Kim Myung Joon Song Soon Yeong Ko Suk Bae Kim Source Type: research
Comparison of Glecaprevir/Pibrentasvir and Sofosbuvir/Ledipasvir in Patients with Hepatitis C Virus Genotype 1 and 2 in South Korea
CONCLUSIONS: Both regimens had similar treatment completion rates, effectiveness, and safety profiles. Therefore, the SOF/LDV regimen can also be considered a viable DAA for the treatment of patients with genotype 1 or 2 chronic hepatitis C.PMID:38522854 | DOI:10.4166/kjg.2023.141 (Source: Korean J Gastroenter...)
Source: Korean J Gastroenter... - March 24, 2024 Category: Gastroenterology Authors: Hyun Deok Shin Il Han Song Sae Hwan Lee Hong Soo Kim Tae Hee Lee Hyuk Soo Eun Seok Hyun Kim Byung Seok Lee Hee Bok Chae Seok Hwan Kim Myung Joon Song Soon Yeong Ko Suk Bae Kim Source Type: research
Comparison of Glecaprevir/Pibrentasvir and Sofosbuvir/Ledipasvir in Patients with Hepatitis C Virus Genotype 1 and 2 in South Korea
CONCLUSIONS: Both regimens had similar treatment completion rates, effectiveness, and safety profiles. Therefore, the SOF/LDV regimen can also be considered a viable DAA for the treatment of patients with genotype 1 or 2 chronic hepatitis C.PMID:38522854 | DOI:10.4166/kjg.2023.141 (Source: Korean J Gastroenter...)
Source: Korean J Gastroenter... - March 24, 2024 Category: Gastroenterology Authors: Hyun Deok Shin Il Han Song Sae Hwan Lee Hong Soo Kim Tae Hee Lee Hyuk Soo Eun Seok Hyun Kim Byung Seok Lee Hee Bok Chae Seok Hwan Kim Myung Joon Song Soon Yeong Ko Suk Bae Kim Source Type: research
Comparison of Glecaprevir/Pibrentasvir and Sofosbuvir/Ledipasvir in Patients with Hepatitis C Virus Genotype 1 and 2 in South Korea
CONCLUSIONS: Both regimens had similar treatment completion rates, effectiveness, and safety profiles. Therefore, the SOF/LDV regimen can also be considered a viable DAA for the treatment of patients with genotype 1 or 2 chronic hepatitis C.PMID:38522854 | DOI:10.4166/kjg.2023.141 (Source: Korean J Gastroenter...)
Source: Korean J Gastroenter... - March 24, 2024 Category: Gastroenterology Authors: Hyun Deok Shin Il Han Song Sae Hwan Lee Hong Soo Kim Tae Hee Lee Hyuk Soo Eun Seok Hyun Kim Byung Seok Lee Hee Bok Chae Seok Hwan Kim Myung Joon Song Soon Yeong Ko Suk Bae Kim Source Type: research
Comparison of Glecaprevir/Pibrentasvir and Sofosbuvir/Ledipasvir in Patients with Hepatitis C Virus Genotype 1 and 2 in South Korea
CONCLUSIONS: Both regimens had similar treatment completion rates, effectiveness, and safety profiles. Therefore, the SOF/LDV regimen can also be considered a viable DAA for the treatment of patients with genotype 1 or 2 chronic hepatitis C.PMID:38522854 | DOI:10.4166/kjg.2023.141 (Source: Korean J Gastroenter...)
Source: Korean J Gastroenter... - March 24, 2024 Category: Gastroenterology Authors: Hyun Deok Shin Il Han Song Sae Hwan Lee Hong Soo Kim Tae Hee Lee Hyuk Soo Eun Seok Hyun Kim Byung Seok Lee Hee Bok Chae Seok Hwan Kim Myung Joon Song Soon Yeong Ko Suk Bae Kim Source Type: research
Comparison of Glecaprevir/Pibrentasvir and Sofosbuvir/Ledipasvir in Patients with Hepatitis C Virus Genotype 1 and 2 in South Korea
CONCLUSIONS: Both regimens had similar treatment completion rates, effectiveness, and safety profiles. Therefore, the SOF/LDV regimen can also be considered a viable DAA for the treatment of patients with genotype 1 or 2 chronic hepatitis C.PMID:38522854 | DOI:10.4166/kjg.2023.141 (Source: Korean J Gastroenter...)
Source: Korean J Gastroenter... - March 24, 2024 Category: Gastroenterology Authors: Hyun Deok Shin Il Han Song Sae Hwan Lee Hong Soo Kim Tae Hee Lee Hyuk Soo Eun Seok Hyun Kim Byung Seok Lee Hee Bok Chae Seok Hwan Kim Myung Joon Song Soon Yeong Ko Suk Bae Kim Source Type: research
Comparison of Glecaprevir/Pibrentasvir and Sofosbuvir/Ledipasvir in Patients with Hepatitis C Virus Genotype 1 and 2 in South Korea
CONCLUSIONS: Both regimens had similar treatment completion rates, effectiveness, and safety profiles. Therefore, the SOF/LDV regimen can also be considered a viable DAA for the treatment of patients with genotype 1 or 2 chronic hepatitis C.PMID:38522854 | DOI:10.4166/kjg.2023.141 (Source: Korean J Gastroenter...)
Source: Korean J Gastroenter... - March 24, 2024 Category: Gastroenterology Authors: Hyun Deok Shin Il Han Song Sae Hwan Lee Hong Soo Kim Tae Hee Lee Hyuk Soo Eun Seok Hyun Kim Byung Seok Lee Hee Bok Chae Seok Hwan Kim Myung Joon Song Soon Yeong Ko Suk Bae Kim Source Type: research
Comparison of Glecaprevir/Pibrentasvir and Sofosbuvir/Ledipasvir in Patients with Hepatitis C Virus Genotype 1 and 2 in South Korea
CONCLUSIONS: Both regimens had similar treatment completion rates, effectiveness, and safety profiles. Therefore, the SOF/LDV regimen can also be considered a viable DAA for the treatment of patients with genotype 1 or 2 chronic hepatitis C.PMID:38522854 | DOI:10.4166/kjg.2023.141 (Source: Korean J Gastroenter...)
Source: Korean J Gastroenter... - March 24, 2024 Category: Gastroenterology Authors: Hyun Deok Shin Il Han Song Sae Hwan Lee Hong Soo Kim Tae Hee Lee Hyuk Soo Eun Seok Hyun Kim Byung Seok Lee Hee Bok Chae Seok Hwan Kim Myung Joon Song Soon Yeong Ko Suk Bae Kim Source Type: research
Comparison of Glecaprevir/Pibrentasvir and Sofosbuvir/Ledipasvir in Patients with Hepatitis C Virus Genotype 1 and 2 in South Korea
CONCLUSIONS: Both regimens had similar treatment completion rates, effectiveness, and safety profiles. Therefore, the SOF/LDV regimen can also be considered a viable DAA for the treatment of patients with genotype 1 or 2 chronic hepatitis C.PMID:38522854 | DOI:10.4166/kjg.2023.141 (Source: Korean J Gastroenter...)
Source: Korean J Gastroenter... - March 24, 2024 Category: Gastroenterology Authors: Hyun Deok Shin Il Han Song Sae Hwan Lee Hong Soo Kim Tae Hee Lee Hyuk Soo Eun Seok Hyun Kim Byung Seok Lee Hee Bok Chae Seok Hwan Kim Myung Joon Song Soon Yeong Ko Suk Bae Kim Source Type: research
